Source:http://linkedlifedata.com/resource/pubmed/id/20144493
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
9
|
| pubmed:dateCreated |
2010-10-29
|
| pubmed:abstractText |
Approximately 4% to 8% of patients with HIV-1 treated with abacavir present a hypersensitivity reaction (HSR). Various studies have shown a direct association between human leukocyte antigen (HLA)-B*5701 and HSR to abacavir. The objective of this study was to analyze whether systematic HLA-B*5701 testing to prevent HSR in patients treated with abacavir is a cost-effective option for the Spanish National Health System.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Nov
|
| pubmed:issn |
1578-1852
|
| pubmed:author | |
| pubmed:copyrightInfo |
Copyright © 2009 Elsevier España, S.L. All rights reserved.
|
| pubmed:issnType |
Electronic
|
| pubmed:volume |
28
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
590-5
|
| pubmed:meshHeading |
pubmed-meshheading:20144493-Anti-HIV Agents,
pubmed-meshheading:20144493-Cost-Benefit Analysis,
pubmed-meshheading:20144493-Dideoxynucleosides,
pubmed-meshheading:20144493-Drug Hypersensitivity,
pubmed-meshheading:20144493-HIV Seropositivity,
pubmed-meshheading:20144493-HLA-B Antigens,
pubmed-meshheading:20144493-Humans,
pubmed-meshheading:20144493-Models, Economic,
pubmed-meshheading:20144493-Spain
|
| pubmed:year |
2010
|
| pubmed:articleTitle |
Cost-effectiveness analysis of HLA-B*5701 typing in the prevention of hypersensitivity to abacavir in HIV+ patients in Spain.
|
| pubmed:affiliation |
Oblikue Consulting, Barcelona, Spain. diana.nieves@oblikue.com
|
| pubmed:publicationType |
Journal Article
|